{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:06:47Z","timestamp":1784624807344,"version":"3.55.0"},"reference-count":20,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 CA249811-01A1"],"award-info":[{"award-number":["1R01 CA249811-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TTUHSC Rural Cancer Collaborative"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Immunotherapies integrating immune checkpoint inhibitors (ICI) represent the current standard of care for many solid cancers, yet they effectively treat only a minority of patients due to intrinsic or acquired resistance mechanisms [...]<\/jats:p>","DOI":"10.3390\/vaccines14070639","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:14:27Z","timestamp":1784621667000},"page":"639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and Future Perspectives for Vaccines Targeting the Tumor Microenvironment"],"prefix":"10.3390","volume":"14","author":[{"given":"Devin B.","family":"Lowe","sequence":"first","affiliation":[{"name":"Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Feizi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-4444","authenticated-orcid":false,"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"name":"Departments of Immunology, Pathology and Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41590-025-02308-2","article-title":"Cancer vaccines as enablers of immunotherapy","volume":"26","author":"Khleif","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., and Castelli, C. (2016). Targeting immune regulatory networks to counteract immune suppression in cancer. Vaccines, 4.","DOI":"10.3390\/vaccines4040038"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-026-02710-8","article-title":"Immune modulatory vaccines targeting tumor microenvironment antigens: Recent advances in oncology and beyond","volume":"11","author":"Andersen","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e003675","DOI":"10.1136\/jitc-2021-003675","article-title":"Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma","volume":"9","author":"Storkus","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cecil, D.L., Herendeen, D., Slota, M., O\u2019Meara, M.M., Dang, Y., Corulli, L., and Disis, M.L. (2025). Identification and validation of Th1-selective epitopes derived from proteins overexpressed in breast cancer stem cells. Vaccines, 13.","DOI":"10.3390\/vaccines13050525"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Taylor, J.L., Kokolus, K.M., Basse, P.H., Filderman, J.N., Cosgrove, C.E., Watkins, S.C., Gambotto, A., Lowe, D.B., Edwards, R.P., and Kalinski, P. (2024). Therapeutic anti-tumor efficacy of DC-based vaccines targeting TME-associated antigens is improved when combined with a chemokine-modulating regimen and\/or anti-PD-L1. Vaccines, 12.","DOI":"10.3390\/vaccines12070777"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cheng, X., Liu, Z., Cai, J., Yu, X., Guo, C., Liu, W., Manjili, M.H., Shah, S.A., Repasky, E.A., and Subjeck, J.R. (2025). A novel chaperone-based cancer vaccination enhances immunotherapeutic responsiveness through T cell amplification and tumor immune remodeling. Vaccines, 13.","DOI":"10.3390\/vaccines13111096"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Roy, O., and Anderson, K.S. (2025). Engineering anti-tumor immunity: An immunological framework for mRNA cancer vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13121222"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gazouli, I., Bafaloukos, D., Koutserimpas, C., and Samonis, G. (2025). Individualized mRNA vaccines in melanoma-Where do we stand?. Vaccines, 13.","DOI":"10.3390\/vaccines13090986"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, Y., Han, R., and Ling, C. (2025). Unlocking mRNA vaccine potential in liver cancer treatment via synergistic bile acid modulation. Vaccines, 13.","DOI":"10.3390\/vaccines13050502"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Raju, T.K., Tadic, S., Garrido, P., Ochoa-Callejero, L., Narro-\u00cd\u00f1iguez, J., Garc\u00eda-Sanmart\u00edn, J., and Mart\u00ednez, A. (2025). A DNA vaccine against proadrenomedullin N-terminal 20 peptide (PAMP) reduces angiogenesis and increases lymphocyte and macrophage infiltration but has no effect on tumor burden in a mouse model of lung metastasis. Vaccines, 13.","DOI":"10.3390\/vaccines13060586"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lim, L., Hu, M.-H., Fan, D., Tu, H.-F., Tsai, Y.-C., Cheng, M., Wang, S., Chang, C.-L., Wu, T.-C., and Hung, C.-F. (2024). STAT1-Deficient HPV E6\/E7-Associated Cancers Maintain Host Immunocompetency against Therapeutic Intervention. Vaccines, 12.","DOI":"10.3390\/vaccines12040430"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lien, A.C., Johnson, G.S., Guan, T., Burns, C.P., Parker, J.M., Dong, L., Wakefield, M.R., and Fang, Y. (2025). The past, present, and future of cervical cancer vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13020201"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gwin, W.R., Salazar, L.G., Dai, J.Y., Higgins, D., Coveler, A.L., Childs, J.S., Blancas, R., Dang, Y., Reichow, J., and Slota, M. (2025). A phase II study of denileukin diftitox in patients with advanced treatment refractory breast cancer. Vaccines, 13.","DOI":"10.3390\/vaccines13020117"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-016-0140-2","article-title":"Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: Immune monitoring and clinical results of a randomized phase II trial","volume":"4","author":"Luke","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines","volume":"112","author":"Morse","year":"2008","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Phung, L.H., Nejo, T., and Okada, H. (2024). Lessons from post-immunotherapy tumor tissues in clinical trials: How can we fuel the tumor microenvironment in gliomas?. Vaccines, 12.","DOI":"10.3390\/vaccines12080862"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:44:02Z","timestamp":1784623442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070639"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070639","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}